X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (53) 53
index medicus (49) 49
humans (42) 42
male (27) 27
prostate cancer (23) 23
cancer (22) 22
middle aged (17) 17
tumors (17) 17
aged (16) 16
melanoma (16) 16
metastasis (14) 14
female (13) 13
metastases (13) 13
survival (13) 13
adult (12) 12
mutation (12) 12
patients (12) 12
care and treatment (11) 11
therapy (10) 10
antineoplastic agents - therapeutic use (9) 9
neoplasms - drug therapy (9) 9
poly polymerase inhibitors (9) 9
treatment outcome (9) 9
analysis (8) 8
clinical trials (8) 8
prostatic neoplasms - pathology (8) 8
urology & nephrology (8) 8
aged, 80 and over (7) 7
castration (7) 7
diagnosis (7) 7
genetic aspects (7) 7
immunotherapy (7) 7
neoplasm metastasis (7) 7
neoplasm staging (7) 7
ovarian-cancer (7) 7
pharmacology & pharmacy (7) 7
poly polymerase (7) 7
research (7) 7
solid tumors (7) 7
animals (6) 6
dna repair (6) 6
enzyme inhibitors - therapeutic use (6) 6
homologous recombination (6) 6
prostate (6) 6
prostatic neoplasms - drug therapy (6) 6
antineoplastic agents - pharmacology (5) 5
biopsy (5) 5
brca2 protein - genetics (5) 5
cells (5) 5
chemotherapy (5) 5
computed tomography (5) 5
docetaxel (5) 5
double-blind (5) 5
guidelines (5) 5
health aspects (5) 5
ipilimumab (5) 5
monoclonal antibodies (5) 5
mutations (5) 5
olaparib (5) 5
parp inhibitors (5) 5
prognosis (5) 5
progression (5) 5
prostatic neoplasms - genetics (5) 5
prostatic neoplasms, castration-resistant - drug therapy (5) 5
toxicity (5) 5
abiraterone acetate (4) 4
abridged index medicus (4) 4
adp-ribose polymerase (4) 4
antineoplastic agents (4) 4
biomarkers (4) 4
circulating tumor-cells (4) 4
clinical-trials (4) 4
dna (4) 4
dna damage (4) 4
drug resistance, neoplasm (4) 4
enzyme inhibitors - pharmacology (4) 4
gene mutations (4) 4
hematology, oncology and palliative medicine (4) 4
medical imaging (4) 4
medical research (4) 4
medicine, general & internal (4) 4
melanoma - drug therapy (4) 4
men (4) 4
open-label (4) 4
ovarian cancer (4) 4
pharmacology (4) 4
phthalazines - therapeutic use (4) 4
physiological aspects (4) 4
piperazines - therapeutic use (4) 4
prostate-specific antigen (4) 4
prostatic neoplasms, castration-resistant - pathology (4) 4
quality of life (4) 4
resistant prostate-cancer (4) 4
retrospective studies (4) 4
trial (4) 4
adenocarcinoma - drug therapy (3) 3
antimitotic agents (3) 3
article (3) 3
base excision-repair (3) 3
braf (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 882 - 892
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 7, pp. 722 - 723
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 18, pp. 1697 - 1708
Journal Article
The Lancet Oncology, ISSN 1470-2045, 05/2018, Volume 19, Issue 5, pp. 672 - 681
Nivolumab monotherapy and combination nivolumab plus ipilimumab increase proportions of patients achieving a response and survival versus ipilimumab in... 
TRIAL | DABRAFENIB | SURVIVAL | ONCOLOGY | MUTANT MELANOMA | TRAMETINIB | DOUBLE-BLIND | OPEN-LABEL | Brain | Analysis | Metastasis | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Cancer Forum, ISSN 0311-306X, 04/2018, Volume 42, Issue 1
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 825 - 833
Journal Article
Journal Article
Journal of Hepatology, ISSN 0168-8278, 10/2018, Volume 69, Issue 4, pp. 976 - 978
Journal Article
The Journal of Pathology, ISSN 0022-3417, 02/2013, Volume 229, Issue 3, pp. 422 - 429
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2013, Volume 71, Issue 4, pp. 1041 - 1050
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 05/2011, Volume 8, Issue 5, pp. 302 - 306
Background. A 58-year-old woman presented with metastatic endometrioid endometrial adenocarcinoma after being previously treated with surgery and adjuvant... 
POLY(ADP-RIBOSE) POLYMERASE | INSTABILITY | THERAPEUTIC STRATEGY | ONCOLOGY | MUTANT-CELLS | BREAK REPAIR | MUTATION | INHIBITORS | TUMORS | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - pathology | Brain Neoplasms - secondary | Peritoneal Neoplasms - drug therapy | Endometrial Neoplasms - genetics | Lung Neoplasms - secondary | Female | Adenocarcinoma - genetics | Liver Neoplasms - secondary | Peritoneal Neoplasms - secondary | Lung Neoplasms - genetics | PTEN Phosphohydrolase - genetics | Carcinoma, Endometrioid - genetics | PTEN Phosphohydrolase - deficiency | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Brain Neoplasms - genetics | Treatment Outcome | Piperazines - therapeutic use | Brain Neoplasms - drug therapy | Carcinoma, Endometrioid - drug therapy | Adenocarcinoma - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Phthalazines - therapeutic use | Peritoneal Neoplasms - genetics | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Neoplasm Recurrence, Local - genetics | Carcinoma, Endometrioid - pathology | Case studies | Antimitotic agents | Care and treatment | Usage | Endometrial cancer | Gene mutations | Patient outcomes | Diagnosis | Antineoplastic agents | Health aspects | Risk factors | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2017, Volume 35, Issue 34, pp. 3792 - 3794
Journal Article
Current Drug Targets, ISSN 1389-4501, 12/2011, Volume 12, Issue 14, pp. 2034 - 2044
Poly(ADP-ribose) polymerase (PARP) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP... 
BRCA1 | Synthetic lethality | BRCA2 | Homologous recombination | PARP inhibitors | THERAPEUTIC STRATEGY | synthetic lethality | DNA-DAMAGE | DOUBLE-STRAND BREAKS | IMPROVED SURVIVAL | OVARIAN-CANCER | homologous recombination | BASE EXCISION-REPAIR | ADP-RIBOSE POLYMERASE | PHARMACOLOGY & PHARMACY | IONIZING-RADIATION
Journal Article